Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shendi Granules
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Anhui University of Chinese Medicine
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Shendi Granules (参地颗粒) is a Traditional Chinese Medicine (TCM) herbal formulation developed by the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine. It is primarily indicated for the treatment of chronic glomerulonephritis (CGN), particularly in patients diagnosed with spleen and kidney deficiency syndrome. The formulation is designed to address immune imbalances by modulating the PD-1/PD-L1 signaling pathway and reducing the levels of pro-inflammatory and pro-fibrotic markers, including monocyte chemoattractant protein-1 (MCP-1) and transforming growth factor-beta 1 (TGF-β1). Clinical research indicates that Shendi Granules, when used as an adjunct to conventional therapy, may help reduce proteinuria and slow the progression of renal damage.
- Other names
- 参地颗粒Shendi Keli
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)PDCD1 (Programmed cell death protein 1 receptor)CCL2 (C-C motif chemokine 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on Shendi Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shendi Granules.